Intelligence · Patent portfolio
PTC THERAPEUTICS Patents
Full USPTO pharma patent portfolio for PTC THERAPEUTICS — grant dates, expiration, and drug cross-links.
- Patents
- 149
- Expiring ≤24m
- 3
Quick answer
PTC THERAPEUTICS has 149 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.
-
US 7304080
Substituted 1,2,4-oxadiazoles, compositions and methods of use
granted -
US 7291603
Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
granted -
US 7202262
Benzoic acid or benzoate substituted 1,2,4-oxadiazole compounds and their use for the treatment of disease
granted -
US 6992096
1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
expired -
US 6875736
Methods for identifying RNA binding compounds
expired
Frequently asked questions
How many patents does PTC THERAPEUTICS have?
149 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do PTC THERAPEUTICS patents expire?
3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory